|Bid||0.00 x 900|
|Ask||0.00 x 4000|
|Day's Range||105.58 - 106.67|
|52 Week Range||79.11 - 113.41|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||38.93|
|Earnings Date||Apr 30, 2021|
|Forward Dividend & Yield||5.20 (4.81%)|
|Ex-Dividend Date||Apr 14, 2021|
|1y Target Est||122.17|
For instance, the S&P 500's cyclically adjusted price-to-earnings ratio -- a measure of the stock market's valuation -- is currently 36.6, the highest it has been in more than 10 years. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie currently trades for just 8.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.19.
The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq.
Top Research Reports for Home Depot, Toyota & IBM